SCHEDULE: Venrock Maintains 9.9% Stake in Vor Biopharma

Venrock Healthcare Capital Partners reports a 9.9% beneficial ownership stake in Vor Biopharma Inc. as of March 31, 2026.

Summary

• Venrock Healthcare Capital Partners and affiliated entities disclosed a 9.9% beneficial ownership stake in Vor Biopharma Inc.
• The holding consists of 5,083,877 shares, including common stock and pre-funded warrants.
• The reporting group includes Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, and Venrock Healthcare Capital Partners EG, L.P.
• The filing confirms that the investment is held for passive purposes and not to influence control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral disclosure of existing institutional ownership, indicating stability in the shareholder base rather than a new strategic shift.

Positives

• Continued institutional support from a specialized healthcare investment firm.
• The reporting group maintains a significant 9.9% stake, signaling long-term interest in the company's development.

Negatives

• The stake is capped at 9.9% due to a beneficial ownership blocker in the pre-funded warrants, limiting immediate voting power expansion.

Risks

• The investment is subject to a 9.99% ownership blocker, which restricts the exercise of pre-funded warrants if it would exceed this threshold.
• The value of the holding is tied to the performance of Vor Biopharma's clinical pipeline and market volatility.

Future Outlook

The filing does not provide specific forward-looking guidance on the company's operations, as it is a disclosure of beneficial ownership.

Industry Context

StockSavvy.ai notes that this filing reflects standard institutional portfolio management within the biotechnology sector, where specialized venture firms often maintain significant stakes in clinical-stage companies to support long-term development milestones.

Comparison to Industry Standards

• The 9.9% ownership threshold is a common benchmark for institutional investors to avoid triggering more stringent regulatory reporting requirements associated with 'control' positions.

Stakeholder Impact

• Provides transparency to shareholders regarding the concentration of ownership by institutional investors.

Next Steps

• Continued monitoring of the issuer's share count and potential future filings if ownership thresholds change.

Key Dates

Keywords

Vor Biopharma, Venrock, Schedule 13G, Biotech, Institutional Ownership, Pre-funded Warrants